Solid Biosciences Inc. filings document regulatory disclosures for a Nasdaq-listed precision genetic medicine company developing gene therapies for rare neuromuscular and cardiac diseases. Its SEC records include Form 8-K reports on operating and financial results, Regulation FD presentations, clinical updates for SGT-003 and the INSPIRE DUCHENNE trial, material agreements, and capital-structure matters.
Proxy filings describe annual stockholder meeting proposals, board classification matters, advisory votes, executive compensation, and equity awards. The filing record also identifies the company’s common stock as listed on The Nasdaq Global Select Market under the SLDB symbol.
A holder of SLDB common stock, Paul Herzich, has filed a notice of intent to sell up to 26,250 shares through E*TRADE on the NASDAQ, with an aggregate market value of $168,968.63. The issuer had 82,561,235 shares outstanding and the approximate sale date is February 2, 2026.
The shares to be sold were acquired on February 2, 2026 via settlement of performance shares from the issuer as compensation. Over the prior three months, Herzich sold 2,701 shares of common stock on December 3, 2025, generating gross proceeds of $13,802.11.
Solid Biosciences Inc. director Ilan Ganot reported routine equity compensation activity and a small tax-related share sale. On January 27, 2026, previously granted restricted stock units converted one-for-one into common stock, including 389 shares for his wife and 3,884 shares for him.
On January 28, 2026, 191 common shares indirectly held through his wife were sold at $6.59 per share to cover withholding taxes under a pre-established automatic sell-to-cover instruction and were not a discretionary trade. Following these events, he beneficially owns 95,255 shares individually, 4,042 shares jointly with Annie Ganot, 17,476 shares indirectly through his wife, and 19,394 shares through the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences Inc. CFO & Treasurer Kevin Tan reported routine equity transactions. On January 9, 2026, 11,250 restricted stock units (RSUs) converted into the same number of common shares at an exercise price of $0.00, reflecting scheduled vesting. On January 13, 2026, he sold 5,704 shares of common stock at $5.27 per share.
According to the disclosure, this sale was made solely to cover withholding taxes under an automatic “sell-to-cover” instruction adopted on August 15, 2024, and is described as not a discretionary trade by Mr. Tan. After these transactions, he directly holds 46,100 shares of common stock and 11,250 RSUs, with RSUs converting to common stock on a one-for-one basis and vesting in four equal annual installments from January 9, 2023.
A holder of SLDB common stock filed a notice of proposed sale on Form 144 covering 5,704 shares. These shares were acquired on 01/09/2026 through the settlement of vested restricted stock units from the issuer as compensation. The planned sale is indicated through E*TRADE Financial Corporation, with an approximate aggregate market value of 30,060.08 and an expected sale date of 01/13/2026 on the NASDAQ. The issuer reports 79,162,201 common shares outstanding, providing context for the relative size of this planned transaction.
Solid Biosciences director Ian F. Smith reported multiple equity award transactions. On 01/02/2026, he received a stock option for 18,012 shares of common stock at an exercise price of $5.45 per share and a grant of 13,761 restricted stock units (RSUs). These “Smith Equity Awards” vest in equal quarterly installments over 12 months from the grant date, with full acceleration if the Smith Agreement ends early or there is a change in control of the company.
On 01/06/2026, 4,573 previously granted RSUs fully vested and converted to 4,573 shares of common stock on a one‑for‑one basis. After these transactions, Smith directly held 131,264 shares of Solid Biosciences common stock, along with 18,012 options and 13,761 RSUs.
Solid Biosciences Inc. director Ilan Ganot reported equity transactions related to spouse-held awards and updated his share holdings. On January 3, 2026, 2,994 restricted stock units held by his wife converted into 2,994 shares of common stock, reflecting one-for-one conversion of these awards. On January 5, 2026, 1,053 shares of common stock associated with his wife were sold at $5.43 per share to cover withholding taxes after the vesting of previously granted restricted stock units, and the filing notes these sales do not represent a discretionary trade by Ms. Ganot.
Following these transactions, 17,278 shares of common stock are reported as indirectly owned through his wife. The filing also reports 95,413 shares of common stock held directly by Mr. Ganot (including shares held jointly with Annie Ganot) and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust, for which Adam and Annie Ganot serve as trustees.
Solid Biosciences (SLDB) director Ilan Ganot reported an open-market sale of common stock. On 11/10/2025, he sold 3,278 shares at a weighted average price of $4.12, executed in multiple trades within a $4.11–$4.12 range.
Following the transaction, he beneficially owned 95,412 shares directly. Additional indirect holdings reported include 14,839 shares held by his spouse and 19,394 shares held in the Ilan Ganot 2017 Irrevocable Trust.
Solid Biosciences (SLDB) filed its Q3 2025 report, posting a net loss of $45.8 million, driven by higher R&D as clinical programs advanced. R&D was $38.9 million (vs. $27.3 million a year ago) and G&A was $9.2 million (vs. $7.9 million). Total operating expenses reached $48.1 million.
Liquidity remained strong with $236.1 million in cash, cash equivalents and available-for-sale securities as of September 30, 2025, and management indicates funding into the first half of 2027. The company strengthened its balance sheet earlier in the year via the February 2025 offering, yielding approximately $188.0 million in net proceeds and pre-funded warrants. Derivative liabilities tied to FA212 milestones were $6.6 million at quarter-end.
Pipeline updates included progress in SGT-003 (Duchenne), with interim data (as of September 29, 2025) described in the filing, ongoing screening for SGT-212 (FA), and IND/CTA clearances for SGT-501 (CPVT). Shares outstanding were 77,910,239 as of October 29, 2025.
Solid Biosciences (SLDB) filed an 8‑K announcing positive interim clinical data and a corporate update for SGT‑003, its gene therapy for Duchenne muscular dystrophy. The Phase 1/2 INSPIRE DUCHENNE trial has dosed 23 participants across 15 sites, with dosing expected to reach 30 by early 2026.
At Day 90 (N=10, ages 5–10), mean microdystrophin expression was 58% by western blot and mass spectrometry, and 51% microdystrophin‑positive fibers by immunofluorescence. Strong correlations linked microdystrophin to restoration of DAPC components, including beta‑sarcoglycan (0.95) and nNOS activity (0.95). Biomarkers of muscle injury improved, with mean reductions at Day 90 in CK, ALT, AST and LDH, and further improvements observed in limited Day 360 data. Early cardiac monitoring showed LVEF trending into normal ranges at Day 180 (N=8) and cTnI reductions.
Safety was generally favorable with steroids alone for prophylaxis; one treatment‑related Grade 3 immune‑mediated myositis resolved after steroid treatment, and dosing continued. The company plans to meet the FDA in the first half of 2026 to discuss potential registrational pathways and has initiated the Phase 3 IMPACT DUCHENNE study outside the U.S., with approvals in Canada and Australia.
Solid Biosciences (SLDB) Form 4: Chief Medical Officer Gabriel Brooks reported RSU vesting and a related tax sale. On 10/18/2025, 9,750 restricted stock units converted to common stock on a one-for-one basis. On 10/20/2025, 2,895 shares were sold at $5.96 to cover withholding taxes under a previously adopted durable automatic sale instruction letter, characterized as a sell-to-cover and not a discretionary trade.
Following these transactions, Brooks beneficially owned 33,819 common shares, held directly. The filing notes an additional 19,500 RSUs beneficially owned after the reported transactions. The RSU grant from 10/18/2023 vests over four years at 25% on each anniversary of the grant date.